Table 6.

Objective radiologic assessment of tumor response in 10 patients who had clinical evidence of stable disease

PatientTarget lesion(s)Pre-∑D (cm)Interval (d)Post-∑D (cm)% Change vs baselineOverall response
RL05Liver22.96124.2+5.7SD
12421.8-4.8SD
RL06Lung, liver, peritoneum303.574335.2+10.5SD
RL12Lymph node68.76081.4+18.5PD
12372.3+5.2PD
17982.4+19.9PD
RL15Lymph node26.05627.9+7.3SD
12627.8+6.9SD
RL17Liver235.457228.9-2.8SD
RL19Liver98.25691.5-6.8SD
Lymph node8482.1-16.4SD
RL20Lymph node33.55334.0+1.5SD
11137+10.4SD
RL25Lymph node73.054102.4+40.3PD
RL27Liver, pelvis346.173315.1-9.0SD
143276.8-20.0SD
RL31Liver210.271216.8+3.1SD
Lymph node123256.9+22.2PD
  • NOTE: Minor responses were seen at 124, 84, and 143 d in patients RL05, RL19, and RL27, respectively.

    Abbreviations: Pre-∑D, sum of longest diameters of target lesions before start of reovirus treatment; Post-∑D, sum of longest diameters of target lesions after reovirus treatment; SD, stable disease; PD, progressive disease.